Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;12(3):38-48.
doi: 10.1007/s40135-024-00321-6. Epub 2024 Feb 23.

Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy

Affiliations

Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy

Zachary Snow et al. Curr Ophthalmol Rep. 2024 Sep.

Abstract

Purpose of review: We review the latest screening and diagnostic techniques, and the most recent recommendations on the management of hydroxychloroquine retinopathy.

Recent findings: Hydroxychloroquine (HCQ) has been shown to cause retinal toxicity in a dose-dependent fashion. Early diagnosis is critical as the resultant retinopathy is not reversible. New imaging modalities, such as adaptive optics (AO), microperimetry, and retro-mode imaging, may show promise in the timely diagnosis of HCQ retinopathy.

Summary: Automated visual fields and spectral-domain optical coherence tomography (SD-OCT) are the primary tests used in routine screening for HCQ retinopathy, but fundus autofluorescence (FAF) and multifocal electroretinogram (mfERG) have also been shown to be useful. A baseline ophthalmologic examination is recommended in all patients beginning long-term hydroxychloroquine therapy within the first year of starting therapy. Automated visual fields and SD-OCT should be included during this baseline exam in patients with pre-existing macular conditions. Afterwards, annual screening can be deferred for the first 5 years of HCQ treatment unless the patient has a major risk factor.

Keywords: Bull’s Eye maculopathy; Bull’s Eye retinopathy; Hydroxychloroquine retinopathy; Hydroxychloroquine toxicity; Plaquenil retinopathy; Plaquenil toxicity.

PubMed Disclaimer

Conflict of interest statement

Competing interests Not applicable

Figures

Figure 1.
Figure 1.
A. Color fundus photo of the left eye demonstrating “Bull’s Eye” maculopathy. Paracentral depigmentation of the retinal pigment epithelium (RPE) that spares the central fovea can be visualized. B. Fundus autofluorescence (FAF) photo of the left eye showing parafoveal hypo autofluorescence due to the low level RPE metabolic activity with underlying local atrophy with secondary photoreceptor loss. C. Optical coherence tomography (OCT) of the macula showing significant loss of the parafoveal photoreceptor inner segment/outer segment (IS/OS) junction and thinning of the outer retina with RPE irregularity. D. Humphrey visual field central 10–2 white-on-white pattern demonstrates dense paracentral scotoma.

References

    1. Gabourel JD (1963) Effects of hydroxychloroquine on the growth of mammalian cells in vitro. J Pharmacol Exp Ther 141:122–130 - PubMed
    1. Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD, LUMINA Study Group (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168–1172 - PMC - PubMed
    1. Pons-Estel GJ, Alarcón GS, McGwin G, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM, Lumina Study Group (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61:830–839 - PMC - PubMed
    1. Willis R, Seif AM, McGwin G, et al. (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21:830–835 - PMC - PubMed
    1. Fanouriakis A, Kostopoulou M, Alunno A, et al. (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736–745 - PubMed

LinkOut - more resources